First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)
Clinical trial NCT05749900 · RECRUITING
Trial details
- NCT number
- NCT05749900
- Sponsor
- Yonsei University
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-05-12
- Primary completion
- 2026-02-28
- Enrollment
- 44
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.